Linked Life Data

15716329

Source:http://linkedlifedata.com/resource/pubmed/id/15716329

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-3-24
pubmed:abstractText
Increased (intra)renal activity of the renin-angiotensin system may cause a persistent increase in renovascular resistance and intraglomerular pressure in patients with diabetes, thus contributing to the development of diabetic renal damage. The effect of chronic angiotensin II subtype 1 receptor blockade on (intra)renal hemodynamics in patients with type 2 diabetes was examined in a double-blind parallel group study. Patients were treated with 40 mg of olmesartan (n = 19) or placebo (n = 16), and renal hemodynamics were assessed before and after 12 wk of treatment using inulin and para-aminohippurate clearance techniques. Olmesartan significantly reduced 24-h ambulatory systolic and diastolic BP (both P < 0.05). In parallel, effective renal plasma flow increased significantly from 602 +/- 76 to 628 +/- 87 ml/min per 1.73 m(2), whereas filtration fraction and renovascular resistance decreased significantly (all P < 0.05). With placebo treatment, effective renal plasma flow decreased and filtration fraction increased significantly (both P < 0.05). GFR was not affected by both treatments. Active plasma renin concentration increased considerably (P < 0.05) with olmesartan therapy but remained unchanged with placebo treatment. Nitric oxide metabolism (plasma nitrate and nitrite) and asymmetric dimethylarginine blood levels were not affected by olmesartan and placebo therapy. In contrast, plasma 8-isoprostane 15(S)-8-iso-prostaglandin F(2a) concentration, a biochemical marker of oxidative stress, decreased significantly (P < 0.05) with olmesartan treatment. Chronic angiotensin II subtype 1 receptor blockade decreases (intra)renal vascular resistance and increases renal perfusion despite significant BP reduction. In addition, it significantly reduces oxidative stress. These effects of angiotensin II receptor antagonists may contribute to their beneficial long-term renal effects in patients with type 2 diabetes.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1046-6673
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1135-40
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15716329-Aged, pubmed-meshheading:15716329-Angiotensin II Type 1 Receptor Blockers, pubmed-meshheading:15716329-Blood Pressure, pubmed-meshheading:15716329-Blood Pressure Monitoring, Ambulatory, pubmed-meshheading:15716329-Diabetes Mellitus, Type 2, pubmed-meshheading:15716329-Dinoprost, pubmed-meshheading:15716329-Double-Blind Method, pubmed-meshheading:15716329-Drug Administration Schedule, pubmed-meshheading:15716329-Female, pubmed-meshheading:15716329-Humans, pubmed-meshheading:15716329-Imidazoles, pubmed-meshheading:15716329-Kidney, pubmed-meshheading:15716329-Male, pubmed-meshheading:15716329-Middle Aged, pubmed-meshheading:15716329-Oxidative Stress, pubmed-meshheading:15716329-Renal Circulation, pubmed-meshheading:15716329-Renin, pubmed-meshheading:15716329-Tetrazoles, pubmed-meshheading:15716329-Vascular Resistance
pubmed:year
2005
pubmed:articleTitle
Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes.
pubmed:affiliation
Department of Internal Medicine, Medical School Hannover, Germany. fliser.danilo@mh-hannover.de
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't